GlaxoSmithKline’s former chief executive Andrew Witty was yesterday announced as the new CEO of Optum – a US payer organisation which includes pharmacy benefits manager OptumRx.
GlaxoSmithKline looks set to have another year without US generic competition to its respiratory blockbuster Advair, after the FDA raised problems with a challenger.
GlaxoSmithKline saw its share price fall 6% yesterday after releasing underwhelming figures in Q3, and leaving investors uncertain about its future dividend payments.